| Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart … AP Maggioni, SD Anker, U Dahlström, G Filippatos, P Ponikowski, ... European journal of heart failure 15 (10), 1173-1184, 2013 | 790 | 2013 |
| Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease K Magyar, R Halmosi, A Palfi, G Feher, L Czopf, A Fulop, I Battyany, ... Clinical hemorheology and microcirculation 50 (3), 179-187, 2012 | 405 | 2012 |
| Acute heart failure congestion and perfusion status–impact of the clinical classification on in‐hospital and long‐term outcomes; insights from the ESC‐EORP‐HFA Heart Failure … O Chioncel, A Mebazaa, AP Maggioni, VP Harjola, G Rosano, C Laroche, ... European journal of heart failure 21 (11), 1338-1352, 2019 | 224 | 2019 |
| Effect of poly (ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system R Halmosi, Z Berente, E Osz, K Toth, P Literati-Nagy, B Sumegi Molecular pharmacology 59 (6), 1497-1505, 2001 | 195 | 2001 |
| In‐hospital and 1‐year mortality associated with diabetes in patients with acute heart failure: results from the ESC‐HFA Heart Failure Long‐Term Registry G Targher, M Dauriz, C Laroche, PL Temporelli, M Hassanein, ... European journal of heart failure 19 (1), 54-65, 2017 | 166 | 2017 |
| In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine B Horvath, Z Marton, R Halmosi, T Alexy, L Szapary, J Vekasi, Z Biro, ... Clinical neuropharmacology 25 (1), 37-42, 2002 | 149 | 2002 |
| Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure Long-Term Registry M Canepa, C Fonseca, O Chioncel, C Laroche, MG Crespo-Leiro, ... JACC: Heart Failure 6 (6), 452-462, 2018 | 141 | 2018 |
| Cardioprotective effect of resveratrol in a postinfarction heart failure model A Riba, L Deres, B Sumegi, K Toth, E Szabados, R Halmosi Oxidative medicine and cellular longevity 2017, 2017 | 109 | 2017 |
| Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA … P Rossignol, M Lainscak, MG Crespo‐Leiro, C Laroche, MF Piepoli, ... European journal of heart failure 22 (8), 1378-1389, 2020 | 108 | 2020 |
| Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound P Deres, R Halmosi, A Toth, K Kovacs, A Palfi, T Habon, L Czopf, T Kalai, ... Journal of cardiovascular pharmacology 45 (1), 36-43, 2005 | 99 | 2005 |
| Sex‐and age‐related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long‐Term Registry M Lainąčak, I Milinković, M Polovina, MG Crespo‐Leiro, LH Lund, ... European journal of heart failure 22 (1), 92-102, 2020 | 88 | 2020 |
| PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats E Bartha, I Solti, L Kereskai, J Lantos, E Plozer, K Magyar, E Szabados, ... Cardiovascular research 83 (3), 501-510, 2009 | 86 | 2009 |
| PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3β pathway A Palfi, A Toth, K Hanto, P Deres, E Szabados, Z Szereday, G Kulcsar, ... Journal of molecular and cellular cardiology 41 (1), 149-159, 2006 | 81 | 2006 |
| The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly (ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol … A Pálfi, A Tóth, G Kulcsár, K Hantó, P Deres, E Bartha, R Halmosi, ... Journal of Pharmacology and Experimental Therapeutics 315 (1), 273-282, 2005 | 59 | 2005 |
| The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals T Habon, E Szabados, G Kesmarky, R Halmosi, T Past, B Sumegi, K Toth Cardiovascular research 52 (1), 153-160, 2001 | 58 | 2001 |
| Doxycycline protects against ROS-induced mitochondrial fragmentation and ISO-induced heart failure A Riba, L Deres, K Eros, A Szabo, K Magyar, B Sumegi, K Toth, ... PLoS One 12 (4), e0175195, 2017 | 52 | 2017 |
| Akt activation induced by an antioxidant compound during ischemia-reperfusion A Toth, R Halmosi, K Kovacs, P Deres, T Kalai, K Hideg, K Toth, B Sumegi Free Radical Biology and Medicine 35 (9), 1051-1063, 2003 | 52 | 2003 |
| Scavenger effect of experimental and clinically used cardiovascular drugs Z Marton, R Halmosi, B Horvath, T Alexy, G Kesmarky, J Vekasi, I Battyany, ... Journal of cardiovascular pharmacology 38 (5), 745-753, 2001 | 49 | 2001 |
| The effect of resveratrol on the cardiovascular system from molecular mechanisms to clinical results R Gal, L Deres, K Toth, R Halmosi, T Habon International journal of molecular sciences 22 (18), 10152, 2021 | 48 | 2021 |
| PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms L Deres, E Bartha, A Palfi, K Eros, A Riba, J Lantos, T Kalai, K Hideg, ... PloS one 9 (7), e102148, 2014 | 47 | 2014 |
Kalman TothPécsi Tudományegyetem
